Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients

Clinics

Volumn 65, Issue 10, 2010, Pages 1033-1036

  Carvalho, Filomena M ^a   Bacchi, Livia M ^a   Santos, Priscila P C ^a   Bacchi, Carlos E ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Consultoria em Patologia ^*  (Brazil)

Author keywords

Basal like carcinomas; Breast cancer; Immunohisto chemistry; Triple negative carcinomas; Young women

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6;

ADULT; AGE; BREAST TUMOR; CARCINOMA; CHEMISTRY; CHI SQUARE DISTRIBUTION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; PHENOTYPE; REVIEW;

ADULT; AGE FACTORS; BREAST NEOPLASMS; CARCINOMA; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; MIDDLE AGED; PHENOTYPE;

EID: 78649791571     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322010001000019     Document Type: Review

References (27)

1. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, et al. Effects of young age at presentation on survival in breast cancer, BMC Cancer. 2006;6:194, doi: 10.1186/1471-2407-6-194.
2. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression, J Clin Oncol. 2008;26:3324-3330, doi: 10.1200/JCO.2007.14.2471.
3. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment, PLoS ONE. 2009;4:e7695, doi: 10.1371/journal.pone.0007695.
4. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers, Int J Clin Exp Pathol. 2009;2:444-455.
5. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms, BMC Genomics. 200;7:127, doi: 10.1186/1471-2164-7-127.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours, Nature. 2000;406:747-752, doi: 10.1038/35021093.
7. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32, doi: 10.1002/cncr.22381.
8. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA, Breast Cancer Res Treat. 2009;113:357-370, doi: 10.1007/s10549-008-9926-3.
9. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol. 2009.
10. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721-1728, doi: 10.1002/cncr.22618.
11. Arnes JB, Begin LR, Stefansson I, Brunet JS, Nielsen TO, Foulkes WD, et al. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer, J Clin Pathol. 2009;62:139-146, doi: 10.1136/jcp.2008.056291.
12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374, doi: 10.1158/1078-0432.CCR-04-0220
13. Moinfar F. Is 'basal-like' carcinoma of the breast a distinct clinicopatho-logical entity? A critical review with cautionary notes, Pathobiology. 2008;75:119-131, doi: 10.1159/000123850.
14. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, et al. Invasive ductal carcinoma of the breast with the ''triple-negative'' phenotype: prognostic implications of EGFR immunoreactiv-ity, Breast Cancer Res Treat. 2009;116:317-328, doi: 10.1007/s10549-008-0206-z.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol. 2007;25:118-145, doi: 10.1200/JCO.2006.09.2775.
16. Bacchi LM, Corpa M, Santos PP, Bacchi CE, Carvalho FM. Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: A pathological and immunohistochemical study. Breast. 2010;19:137-141, doi: 10.1016/j.breast.2010.01.002.
17. Rhee J, Han SW, Oh DY, Kim JH, Im SA, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008;8:307, doi: 10.1186/1471-2407-8-307.
18. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice, Adv Anat Pathol. 2007;14:419-430, doi: 10.1097/PAP. 0b013e3181594733.
19. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast, Histopathology. 2006;49:22-34, doi: 10.1111/j.1365-2559.2006.02453.x.
20. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cyto-keratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688-694, doi: 10. 1007/s00428-005-0010-7.
21. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271, doi: 10.1038/modpathol.3800528.
22. Fadare O, Tavassoli FA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol. 2007;14:358-373, doi: 10. 1097/PAP.0b013e31814b26fe.
23. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol. 2008;61:553-560, doi: 10.1136/jcp.2008.055475.
24. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506, doi: 10.1002/path.1916.
25. McAree B, O'Donnell ME, Spence A, Lioe TF, McManus DT, Spence RA. Breast cancer in women under 40years of age: A series of 57 cases from Northern Ireland. Breast. 2010;19:97-104, doi: 10.1016/j.breast.2009.12. 002.
26. Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol. 2009;33:1093-1097, doi: 10.1097/ PAS.0b013e3181b7cb7a
27. Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 2010;116:1234-1242, doi: 10.1002/cncr.24816.